Quarterly Activities/Appendix 4C Cash Flow Report
Released
Released
Announcement PDF
ASX Announcement
31 July 2024
Quarterly Activity Report & Appendix 4C
Q2 FY24
Highlights
•
•
•
Unaudited total revenue of US$0.08m representing a 38% decrease when
compared to US$0.13m in the prior quarter (Q1 FY24)
Ensight 2.0 launched 18 months ahead of schedule, expanding Enlitic’s suite of
available use cases
Three new agreements with global partners, Esaote, Clairvo Technologies and
DataFirst amplify business development reach
Enlitic, Inc. (ASX: ENL) (“Enlitic” or “the Company”), a software development company
that uses artificial intelligence to develop software products that manage medical
imaging data in radiology, today announces its Quarterly Activity Report and Appendix
4C for the three-month period ended 30 June 2024 (“Q2 FY24”).
Michael Sistenich, CEO of Enlitic, said “In the 2nd quarter of 2024, we accelerated the
development of key components of Ensight 2.0 by 18 months. This remarkable
achievement brings an expanded suite of use cases to our clients’ fingertips and
broadens the applicability of our products. Hand in hand with this milestone, we also
made significant inroads into commercialising our product suite at a global level through
our new partnerships with Esaote in Europe, Clairvo Technologies in Japan and DataFirst
in the US. These new partnerships extend our distribution capabilities and further
strengthen our proof-of-concept momentum.
“We continue to focus on strengthening and commercialising our product offering to
further bolster commercial engagement within our client pipeline and remain committed
to continuous improvement and agility to adapt to the evolving demands of our
customers and the healthcare industry.”
Enlitic, Inc.
ARBN 672 254 027
1
Operational Highlights
Customer growth
Enlitic signed three new agreements with partners across the globe, during the quarter. 1
• Enlitic signed a new 3-year distribution agreement with Esaote, one of Europe’s
leading manufacturers of medical diagnostic systems.
• The Company entered into a new distribution agreement with Clairvo
Technologies, distributer of state-of the art technologies to medical care fields in
Japan.
• Enlitic has also signed a 3-year Marketing and Technology agreement with
DataFirst Corporation.
The new partnerships build on recent customer momentum, including new contracts
with Unilabs and Royal National Orthopaedic Hospital NHS Trust, accelerating
commercialisation schedules and serving as an extension of Enlitic’s salesforce to reach
beyond the estimated serviceable market.
Enlitic has begun commercial engagement with a range of existing and potential
customers following the launch of Ensight 2.0 in early June 2024. Enlitic’s open pipeline
opportunity at 30 June 2024 is US$62.4m (US$62.4m at 31 March 2024) 2. Enlitic
continues to focus on the commercialisation of its data standardisation solutions and
building its customer open opportunity pipeline.
Product Development
In June 2024, Enlitic released key components of Ensight 2.0 following the acceleration
of its development roadmap for its data standardisation software, Ensight by 18 months.
This milestone was accomplished by introducing enhancements in AI data models,
DICOM Structured Reporting (the international standard to transmit, store, process, and
display medical imaging information) and HL7 outputs (a range of global standards for
the transfer of clinical and administrative health data between applications) alongside
configurable standardised outputs.
Refer to announcement dated 17 June 2024 for further details.
The dollar values represent the Company’s estimate (based on initial discussions and assessments with each
potential customer) of TCV (the total contracted minimum licence revenue to be charged over the term
(generally 3 years of contracts entered into with customers) of the contract plus ancillary revenue (as
applicable)) of each customer pipeline opportunity if every such opportunity was to result in a signed Licence
Agreement (and the Company has assumed each such Licence Agreement has a term of 3 years). There is no
guarantee that any of the customer pipeline opportunities will result in any contracted clients or contracted
revenue, and the dollar values indicated do not in any way represent an estimate of likely future revenue
arising from those. It merely provides an indication of the potential size of the revenue opportunity presented
by the customer pipeline opportunities.
1
2
Enlitic, Inc.
ARBN 672 254 027
2
Ensight 2.0 integrates the ENDEX™ data standardisation module and the ENCOG™
anonymisation module into a unified software framework, coupled with key
infrastructural components required to deliver the planned common data model. The
new features are successfully driving further customer and partner engagement which is
expected to continue into the second half of 2024.
Enlitic continues to focus on shortening its sales cycle and the conversion of its existing
client pipeline. The release of Ensight 2.0 has enabled us to accelerate the sales
process, whereby the expected time to convert a customer from initial engagement to
signing of contract is anticipated to shorten due to customers’ appetites for the new
product release.
Second Quarter Financial Performance & Cash Flow
Enlitic’s unaudited revenue was US$0.08m, representing a 38% decrease when
compared to US$0.13m in the prior quarter (Q1 FY24) due to an expected timing issue
which was agreed in advance with a Japanese customer and is expected to be rectified
in Q3. Cash receipts for the quarter were US$0.202m, up 102% from US$0.1m in the
previous quarter. This increase is primarily a consequence of the renewal payment for a
key annual contract. The net operating cash outflow for the period was US$3.2m, a
reduction of 12.7% from the previous quarter (Q1 FY24: US$3.6m). The company is
focused on cost efficiencies while it pursues growth. This is reflected by a reduction in
cash expenditure in each area of the business.
Marketing and advertising costs were US$0.07m for the quarter, down 16% in the
previous quarter (Q1 FY24: US$0.08m). Operating costs in Q2 FY24 were US$0.19m and
were down 17.8% from the previous quarter (Q1 FY24: US$0.23m). Administration and
corporate costs were US$0.54m for the quarter, down 4.6% from US$0.56m during the
previous quarter.
Research and development costs for the quarter were US$1.34m, a 9.7% decrease on the
prior quarter (Q1 FY24: US$1.49m). Staff costs of US$1.25m were also down 10.7% on the
previous quarter of US$1.4m. These decreases were in line with expectations.
Enlitic’s cash balance at 30 June 2024 was US$4.3m, down from US$7.4m in the prior
quarter. Enlitic is focused on cost efficiencies at this time and has implemented cost
control measures, where appropriate, to maximise its cash runway during this growth
period.
Enlitic, Inc.
ARBN 672 254 027
3
Use of Funds
Research and development program
Quality and regulatory compliance costs
Strategic development
Sales and marketing
Customer service
Corporate costs
Working capital and administrative costs
Costs of the Offer
Per PreQuotation
Disclosure1 (US$)2
3,812,306
570,167
415,479
3,465,840
1,761,909
1,763,787
921,329
2,147,811
3,366,867
281,142
289,249
1,618,393
766,350
1,485,830
1,035,141
2,393,934
Total
14,858,629
11,236,906
Period ending 30
June 2024 (US$)
As disclosed in Enlitic’s Pre-Quotation Disclosure (released on 18 December 2023), this
reflects the IPO proceeds of US$13.8m along with the cash on hand of US$1.1m prior to
the receipt of IPO proceeds.
2
The use of funds presented in the Company’s Pre-Quotation Disclosure was presented
in AUD. The amounts have been converted to USD (at a rate of 0.67073 which was the
published exchange rate at the Pre-Quotation Disclosure date) as this is the
predominate transacting currency of the Company.
3
Source: Bloomberg
1
The use of funds is broadly in line with Enlitic’s Pre-Quotation Disclosure. Sales and
marketing and customer service are proportionally lower than as stated in the PreQuotation Disclosure however, both expense categories are anticipated to increase from
mid-2024. Both corporate costs and the costs of the offer are proportionally higher than
the Pre-Quotation Disclosure relating to additional complexity associated with listing a
foreign entity on the ASX.
In accordance with ASX Listing Rule 4.7C.3, cash paid for Directors and Non-Executive
Directors in Q2 FY24 amounted to US$137k in aggregate which includes salaries, travel,
and reimbursement of applicable costs.
– ENDS –
Enquiries
Enlitic Investor Relations
Australia:
invest_au@enlitic.com
Enlitic, Inc.
ARBN 672 254 027
USA:
invest@enlitic.com
4
About Enlitic
Enlitic is a software company that uses artificial intelligence to develop software
products that manage medical imaging data in radiology (such as MRI, CT scans, X-ray
and ultrasound images) and licences such products to healthcare providers. Enlitic’s
products (including its current product offering and product suite under development)
seek to standardise, protect, integrate, and analyse data to create the foundation of a
real-world evidence platform that has the ability to improve clinical workflows, increase
efficiencies, and expand capacity. Read more at enlitic.com.
Forward-looking statements
Certain statements made during or in connection with this announcement contain or
comprise certain forward-looking statements regarding the Company, its projected cash
flow, financial performance, its customer contracts and customer pipeline and product
development. Although the Company believes that the expectations reflected in such
forward-looking statements are reasonable, such expectations are only predictions and
are subject to inherent risks and uncertainties which could cause actual values, results,
performance or achievements to differ materially from those expressed, implied or
projected in any forward looking statements and no assurance can be given that such
expectations will prove to have been correct.
Accordingly, results could differ materially from those set out in the forward-looking
statements as a result of, among other factors, changes in economic and market
conditions, delays or changes in product development and realisation of customer
pipeline, changes in demand, success of business and operating initiatives, changes in
the regulatory environment and other government actions, fluctuations in exchange
rates and business and operational risk management.
To the maximum extent permitted by law, each of the Company, its officers, employees
and advisers expressly disclaim any responsibility for the accuracy or completeness of
the material contained in these forward-looking statements and excludes all liability
whatsoever (including in negligence) for any loss or damage which may be suffered by
any person as a consequence of any information in forward-looking statements or any
error or omission. The Company undertakes no obligation to update publicly or release
any revisions to these forward-looking statements to reflect events or circumstances
after today's date or to reflect the occurrence of unanticipated events other than
required by the applicable laws, including the ASX Listing Rules. Accordingly, you should
not place undue reliance on any forward-looking statement.
This announcement was authorised for release by the Board of Enlitic, Inc.
Enlitic, Inc.
ARBN 672 254 027
5
Rule 4.7B
Appendix 4C
Quarterly cash flow report for entities
subject to Listing Rule 4.7B
Name of entity
ENLITIC, INC.
ABN
Quarter ended (“current quarter”)
ARBN 672 254 027
June 30 2024
Consolidated statement of cash flows
Current quarter
$US’000
1.
Cash flows from operating activities
1.1
Receipts from customers
1.2
Payments for
Year to date (6
months)
$US’000
202
302
(1,345)
(2,834)
(b) product manufacturing and operating
costs
(191)
(423)
(c) advertising and marketing
(68)
(149)
-
-
(1,251)
(2,652)
(539)
(1,104)
30
78
-
-
(3,162)
(6,782)
(8)
(18)
(a) research and development
(d) leased assets
(e) staff costs
(f)
administration and corporate costs
1.3
Dividends received (see note 3)
1.4
Interest received
1.5
Interest and other costs of finance paid
1.6
Income taxes paid
1.7
Government grants and tax incentives
1.8
Other (provide details if material)
1.9
Net cash from / (used in) operating
activities
2.
Cash flows from investing activities
2.1
Payments to acquire or for:
(a) entities
(b) businesses
(c) property, plant and equipment
(d) investments
(e) intellectual property
(f)
other non-current assets
ASX Listing Rules Appendix 4C (17/07/20)
+ See chapter 19 of the ASX Listing Rules for defined terms.
Page 1
Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B
Consolidated statement of cash flows
2.2
Current quarter
$US’000
Year to date (6
months)
$US’000
Proceeds from disposal of:
(a) entities
(b) businesses
(c) property, plant and equipment
(d) investments
(e) intellectual property
(f)
other non-current assets
2.3
Cash flows from loans to other entities
2.4
Dividends received (see note 3)
2.5
Other (provide details if material)
2.6
Net cash from / (used in) investing
activities
3.
Cash flows from financing activities
3.1
Proceeds from issues of equity securities
(excluding convertible debt securities)
3.2
Proceeds from issue of convertible debt
securities
3.3
(8)
(18)
-
-
Proceeds from exercise of options
-
1
3.4
Transaction costs related to issues of
equity securities or convertible debt
securities
-
-
3.5
Proceeds from borrowings
-
-
3.6
Repayment of borrowings
-
-
3.7
Transaction costs related to loans and
borrowings
-
-
3.8
Dividends paid
3.9
Other (provide details if material)
3.10
Net cash from / (used in) financing
activities
-
1
4.
Net increase / (decrease) in cash and
cash equivalents for the period
4.1
Cash and cash equivalents at beginning of
period
7,442
11,091
4.2
Net cash from / (used in) operating
activities (item 1.9 above)
(3,162)
(6,782)
4.3
Net cash from / (used in) investing activities
(item 2.6 above)
(8)
(18)
ASX Listing Rules Appendix 4C (17/07/20)
+ See chapter 19 of the ASX Listing Rules for defined terms.
Page 2
Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B
Consolidated statement of cash flows
Current quarter
$US’000
Year to date (6
months)
$US’000
4.4
Net cash from / (used in) financing activities
(item 3.10 above)
-
1
4.5
Effect of movement in exchange rates on
cash held
11
(9)
4.6
Cash and cash equivalents at end of
period
4,282
4,282
5.
Reconciliation of cash and cash
equivalents
Current quarter
$US’000
Previous quarter
$US’000
at the end of the quarter (as shown in the
consolidated statement of cash flows) to the
related items in the accounts
5.1
Bank balances
4,282
7,442
5.2
Call deposits
5.3
Bank overdrafts
5.4
Other (provide details)
5.5
Cash and cash equivalents at end of
quarter (should equal item 4.6 above)
4,282
7,442
6.
Payments to related parties of the entity and their
associates
6.1
Aggregate amount of payments to related parties and their
associates included in item 1
-
6.2
Aggregate amount of payments to related parties and their
associates included in item 2
137
Current quarter
$US'000
Cash Paid for Directors and Non-Executive Directors in quarter 2 amounted to US$137k which includes salaries, travel and
reimbursement of any costs.
ASX Listing Rules Appendix 4C (17/07/20)
+ See chapter 19 of the ASX Listing Rules for defined terms.
Page 3
Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B
7.
Financing facilities
Note: the term “facility’ includes all forms of financing
arrangements available to the entity.
Add notes as necessary for an understanding of the
sources of finance available to the entity.
Total facility
amount at quarter
end
$US’000
Amount drawn at
quarter end
$US’000
7.1
Loan facilities
-
-
7.2
Credit standby arrangements
-
-
7.3
Other (please specify)
-
-
7.4
Total financing facilities
-
-
7.5
Unused financing facilities available at quarter end
7.6
Include in the box below a description of each facility above, including the lender, interest
rate, maturity date and whether it is secured or unsecured. If any additional financing
facilities have been entered into or are proposed to be entered into after quarter end,
include a note providing details of those facilities as well.
8.
Estimated cash available for future operating activities
8.1
Net cash from / (used in) operating activities (item 1.9)
(3,162)
8.2
Cash and cash equivalents at quarter end (item 4.6)
4,282
8.3
Unused finance facilities available at quarter end (item 7.5)
8.4
Total available funding (item 8.2 + item 8.3)
8.5
Estimated quarters of funding available (item 8.4 divided by
item 8.1)
-
$US’000
4,282
1.35
Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as “N/A”. Otherwise, a
figure for the estimated quarters of funding available must be included in item 8.5.
8.6
If item 8.5 is less than 2 quarters, please provide answers to the following questions:
8.6.1
Does the entity expect that it will continue to have the current level of net operating
cash flows for the time being and, if not, why not?
Answer: We expect the currently level of net operating cash flows to continue.
8.6.2
Has the entity taken any steps, or does it propose to take any steps, to raise further
cash to fund its operations and, if so, what are those steps and how likely does it
believe that they will be successful?
Answer: The company is actively considering possible options available to it to fund its
operations. The company will update the market in due course.
8.6.3
Does the entity expect to be able to continue its operations and to meet its business
objectives and, if so, on what basis?
Answer: The company is actively considering possible options available to fund its
operations (and will update the market in due course). Subject to the company
obtaining such additional funding, the company expects to be able to continue its
operations and meet its business objectives.
Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.
ASX Listing Rules Appendix 4C (17/07/20)
+ See chapter 19 of the ASX Listing Rules for defined terms.
Page 4
Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B
Compliance statement
1
This statement has been prepared in accordance with accounting standards and policies
which comply with Listing Rule 19.11A.
2
This statement gives a true and fair view of the matters disclosed.
Date:
31 July 2024
Authorised by: The Board
(Name of body or officer authorising release – see note 4)
Notes
1.
This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the
entity’s activities for the past quarter, how they have been financed and the effect this has had on its cash position. An
entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is
encouraged to do so.
2.
If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions
in, and provisions of, AASB 107: Statement of Cash Flows apply to this report. If this quarterly cash flow report has been
prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the
corresponding equivalent standard applies to this report.
3.
Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities,
depending on the accounting policy of the entity.
4.
If this report has been authorised for release to the market by your board of directors, you can insert here: “By the board”.
If it has been authorised for release to the market by a committee of your board of directors, you can insert here: “By the
[name of board committee – eg Audit and Risk Committee]”. If it has been authorised for release to the market by a
disclosure committee, you can insert here: “By the Disclosure Committee”.
5.
If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as
complying with recommendation 4.2 of the ASX Corporate Governance Council’s Corporate Governance Principles and
Recommendations, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial
records of the entity have been properly maintained, that this report complies with the appropriate accounting standards
and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a
sound system of risk management and internal control which is operating effectively.
ASX Listing Rules Appendix 4C (17/07/20)
+ See chapter 19 of the ASX Listing Rules for defined terms.
Page 5
Share your feedback
Discover